← Back
FeaturedOncology

Zanzalintinib (XL092)

Exelixis

Next-gen MET/VEGFR2 inhibitor. STELLAR-303 (RCC) and STELLAR-007 (mCRPC) Phase 3 readouts to watch.

Renal Cell CarcinomamCRPC

Linked Studies

NCT04685135PrimaryACTIVE_NOT_RECRUITINGPHASE3

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerUpdated Jan 2025
Loading comments…

Also Known As

Development codes

XL092

Other names

zanzalintinib
Search all trials →Request coverage update